罗米地辛联合普拉曲沙的1期研究显示对复发难治性T细胞淋巴瘤有显著活性
这项单中心剂量递增1期研究评估了普拉曲沙联合罗米地辛治疗复发难治性淋巴瘤,29例可评估毒性,3例出现剂量限制性毒性,推荐2期剂量为普拉曲沙25 mg/m2联合罗米地辛12 mg/m2每两周一次,23例可评估疗效,总缓解率57%(13/23),外周T细胞淋巴瘤中为71%(10/14)。
要点
- 推荐2期剂量为普拉曲沙25 mg/m2联合罗米地辛12 mg/m2每两周一次。
- 所有方案中共出现3例剂量限制性毒性:3级口腔黏膜炎2例,4级脓毒症1例。
- 总缓解率57%(13/23),外周T细胞淋巴瘤中71%(10/14)。
核心结论
- 普拉曲沙联合罗米地辛的1期研究在既往治疗的外周T细胞淋巴瘤患者中产生高缓解率。
- 一项针对外周T细胞淋巴瘤的2期研究将确定该联合方案的疗效。
研究设计与样本
- 单中心剂量递增1期研究,纳入复发难治性淋巴瘤患者,设计用于确定剂量限制性毒性、最大耐受剂量、药代动力学特征和缓解率。
- 29例患者入组并可评估毒性。
- 给药方案为普拉曲沙(10至25 mg/m2)联合罗米地辛(12至14 mg/m2),采用3种方案之一:每周×3每28天、每周×2每21天、每两周一次每28天。
- 治疗持续至疾病进展、撤回知情同意或医疗需要。
- 23例患者可评估疗效。
主要发现
- 普拉曲沙与罗米地辛联合给药安全、耐受良好,所有方案中共出现3例剂量限制性毒性(3级口腔黏膜炎2例;4级脓毒症1例)。
- 23例可评估疗效患者的总缓解率为57%(13/23)。
- 外周T细胞淋巴瘤患者的缓解率为71%(10/14)。
关键数值与推荐
- 推荐2期剂量定义为普拉曲沙25 mg/m2联合罗米地辛12 mg/m2每两周一次。
- 罗米地辛获美国食品药品监督管理局批准用于复发难治性外周T细胞淋巴瘤,缓解率25%。
- 普拉曲沙获美国食品药品监督管理局批准用于复发难治性外周T细胞淋巴瘤,缓解率29%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphomas (PTCL) are a group of rare malignancies characterized by chemotherapy resistance and poor prognosis. Romidepsin and pralatrexate were approved by the US Food and Drug Administration for patients with relapsed/refractory PTCL, exhibiting response rates of 25% and 29% respectively. Based on synergy in preclinical models of PTCL, we initiated a phase 1 study of pralatrexate plus romidepsin in patients with relapsed/refractory lymphoma. This was a single institution dose-escalation study of pralatrexate plus romidepsin designed to determine the dose-limiting toxicities (DLTs), maximum tolerated dose, pharmacokinetic profile, and response rates. Patients were treated with pralatrexate (10 to 25 mg/m2) and romidepsin (12 to 14 mg/m2) on 1 of 3 schedules: every week × 3 every 28 days, every week × 2 every 21 days, and every other week every 28 days. Treatment continued until progression, withdrawal of consent, or medical necessity. Twenty-nine patients were enrolled and evaluable for toxicity. Coadministration of pralatrexate and romidepsin was safe, well tolerated, with 3 DLTs across all schedules (grade 3 oral mucositis × 2; grade 4 sepsis × 1). The recommended phase 2 dose was defined as pralatrexate 25 mg/m2 and romidepsin 12 mg/m2 every other week. Twenty-three patients were evaluable for response. The overall response rate was 57% (13/23) across all patients and 71% (10/14) in PTCL. The phase 1 study of pralatrexate plus romidepsin resulted in a high response rate in patients with previously treated PTCL. A phase 2 study in PTCL will determine the efficacy of the combination. This trial was registered at www.clinicaltrials.gov as #NCT01947140.
引用
- Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2017. PMID: 29141948. doi:10.1182/blood-2017-09-806737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。